Connection

Julie Chao to Rats

This is a "connection" page, showing publications Julie Chao has written about Rats.
Connection Strength

3.084
  1. Molecular cloning and expression of rat bradykinin B1 receptor. Biochim Biophys Acta. 1998 Nov 08; 1442(2-3):177-85.
    View in: PubMed
    Score: 0.087
  2. Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. J Am Heart Assoc. 2014 Sep 18; 3(5):e001194.
    View in: PubMed
    Score: 0.066
  3. Molecular cloning and sequence analysis of rat bradykinin B2 receptor gene. Biochim Biophys Acta. 1994 Sep 13; 1219(1):171-4.
    View in: PubMed
    Score: 0.065
  4. Tissue kallikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction. Circ J. 2013; 77(8):2134-44.
    View in: PubMed
    Score: 0.060
  5. Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol. 2012 Oct 15; 303(8):F1230-8.
    View in: PubMed
    Score: 0.056
  6. Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol. 2010 Nov; 299(5):H1419-27.
    View in: PubMed
    Score: 0.049
  7. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension. 2010 Aug; 56(2):260-7.
    View in: PubMed
    Score: 0.049
  8. Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol. 2010 Apr; 298(4):F1033-40.
    View in: PubMed
    Score: 0.047
  9. Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. Am J Physiol Heart Circ Physiol. 2010 Mar; 298(3):H1048-54.
    View in: PubMed
    Score: 0.047
  10. A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. Exp Cell Res. 2010 Feb 01; 316(3):376-89.
    View in: PubMed
    Score: 0.047
  11. Intermedin is a new angiogenic growth factor. Am J Physiol Heart Circ Physiol. 2009 Sep; 297(3):H1040-7.
    View in: PubMed
    Score: 0.046
  12. Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am J Physiol Renal Physiol. 2008 Dec; 295(6):F1735-43.
    View in: PubMed
    Score: 0.043
  13. Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension. 2008 Oct; 52(4):715-20.
    View in: PubMed
    Score: 0.043
  14. Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest. 2008 Nov; 88(11):1157-66.
    View in: PubMed
    Score: 0.043
  15. Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res. 2008 Dec 01; 80(3):354-64.
    View in: PubMed
    Score: 0.043
  16. Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther. 2008 Aug; 19(8):807-19.
    View in: PubMed
    Score: 0.043
  17. Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. Biol Chem. 2008 Jun; 389(6):725-30.
    View in: PubMed
    Score: 0.042
  18. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension. 2008 May; 51(5):1358-65.
    View in: PubMed
    Score: 0.042
  19. Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. Toxicol Sci. 2008 Apr; 102(2):433-43.
    View in: PubMed
    Score: 0.041
  20. Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. Life Sci. 2008 Jan 16; 82(3-4):156-65.
    View in: PubMed
    Score: 0.041
  21. Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol. 2007 Nov; 34(11):2171-6.
    View in: PubMed
    Score: 0.041
  22. Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail. 2007 Sep; 13(7):588-96.
    View in: PubMed
    Score: 0.040
  23. Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension. 2007 Mar; 49(3):490-7.
    View in: PubMed
    Score: 0.038
  24. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept. 2007 Apr 05; 140(1-2):12-20.
    View in: PubMed
    Score: 0.038
  25. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther. 2006 Dec; 17(12):1201-13.
    View in: PubMed
    Score: 0.038
  26. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res. 2007 Jan 01; 73(1):130-42.
    View in: PubMed
    Score: 0.038
  27. Experimental therapy with tissue kallikrein against cerebral ischemia. Front Biosci. 2006 May 01; 11:1323-7.
    View in: PubMed
    Score: 0.037
  28. Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther. 2006 May; 17(5):545-55.
    View in: PubMed
    Score: 0.037
  29. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther. 2006 Feb; 17(2):206-19.
    View in: PubMed
    Score: 0.036
  30. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant. 2006 Mar; 21(3):624-33.
    View in: PubMed
    Score: 0.036
  31. Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. Am J Physiol Renal Physiol. 2005 Sep; 289(3):F622-31.
    View in: PubMed
    Score: 0.034
  32. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci. 2005 Apr 08; 76(21):2457-71.
    View in: PubMed
    Score: 0.034
  33. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum. 2005 Apr; 52(4):1319-24.
    View in: PubMed
    Score: 0.034
  34. Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J Biol Chem. 2005 Mar 04; 280(9):8022-30.
    View in: PubMed
    Score: 0.033
  35. Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int. 2004 Aug; 66(2):722-32.
    View in: PubMed
    Score: 0.032
  36. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension. 2004 Feb; 43(2):452-9.
    View in: PubMed
    Score: 0.031
  37. Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension. 2004 Jan; 43(1):109-16.
    View in: PubMed
    Score: 0.031
  38. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1479-88.
    View in: PubMed
    Score: 0.030
  39. Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1506-14.
    View in: PubMed
    Score: 0.030
  40. Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol. 2002 Aug 01; 22(8):1279-85.
    View in: PubMed
    Score: 0.028
  41. Adenovirus-mediated gene transfer for cardiovascular and renal diseases. Methods Enzymol. 2002; 346:247-63.
    View in: PubMed
    Score: 0.027
  42. A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol. 2001 Nov; 159(5):1797-805.
    View in: PubMed
    Score: 0.027
  43. Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury. Peptides. 2001 Nov; 22(11):1731-7.
    View in: PubMed
    Score: 0.027
  44. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats. Hum Gene Ther. 2000 Sep 01; 11(13):1817-27.
    View in: PubMed
    Score: 0.025
  45. Bradykinin B(1) receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension. 2000 Sep; 36(3):364-70.
    View in: PubMed
    Score: 0.025
  46. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int. 2000 Aug; 58(2):730-9.
    View in: PubMed
    Score: 0.025
  47. Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. Circ Res. 2000 Mar 03; 86(4):418-24.
    View in: PubMed
    Score: 0.024
  48. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension. 2000 Jan; 35(1 Pt 1):25-31.
    View in: PubMed
    Score: 0.024
  49. Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology. 1999 Oct 15; 44(1-2):137-43.
    View in: PubMed
    Score: 0.023
  50. Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats. Clin Exp Hypertens. 1999 Oct; 21(7):1145-60.
    View in: PubMed
    Score: 0.023
  51. Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke. 1999 Sep; 30(9):1925-31; discussion 1931-2.
    View in: PubMed
    Score: 0.023
  52. Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension. 1999 Aug; 34(2):164-70.
    View in: PubMed
    Score: 0.023
  53. Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR. Am J Physiol. 1999 03; 276(3):F476-84.
    View in: PubMed
    Score: 0.022
  54. Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int. 1998 Oct; 54(4):1250-60.
    View in: PubMed
    Score: 0.022
  55. Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int. 1998 May; 53(5):1305-13.
    View in: PubMed
    Score: 0.021
  56. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension. 1998 May; 31(5):1104-10.
    View in: PubMed
    Score: 0.021
  57. Central delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Biochem Biophys Res Commun. 1998 Mar 17; 244(2):449-54.
    View in: PubMed
    Score: 0.021
  58. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther. 1998 Jan 01; 9(1):21-31.
    View in: PubMed
    Score: 0.021
  59. Effect of cyclosporin A on the expression of tissue kallikrein, kininogen, and bradykinin receptor in rat. Am J Physiol. 1997 11; 273(5):F783-9.
    View in: PubMed
    Score: 0.020
  60. Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther. 1997 Oct 10; 8(15):1753-61.
    View in: PubMed
    Score: 0.020
  61. Molecular cloning and expression of rat kallistatin gene. Biochim Biophys Acta. 1997 Sep 12; 1353(3):277-86.
    View in: PubMed
    Score: 0.020
  62. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension. 1997 Sep; 30(3 Pt 1):307-13.
    View in: PubMed
    Score: 0.020
  63. New experimental evidence for a role of tissue kallikrein in hypertension. Nephrol Dial Transplant. 1997 Aug; 12(8):1569-74.
    View in: PubMed
    Score: 0.020
  64. Kallistatin is a potent new vasodilator. J Clin Invest. 1997 Jul 01; 100(1):11-7.
    View in: PubMed
    Score: 0.020
  65. Expression of human tissue kallikrein in rat salivary glands and its secretion into circulation following adenovirus-mediated gene transfer. Immunopharmacology. 1997 Jun; 36(2-3):221-7.
    View in: PubMed
    Score: 0.020
  66. Kallikrein gene therapy: a new strategy for hypertensive diseases. Immunopharmacology. 1997 Jun; 36(2-3):229-36.
    View in: PubMed
    Score: 0.020
  67. Kallikrein gene therapy in newborn and adult hypertensive rats. Can J Physiol Pharmacol. 1997 Jun; 75(6):750-6.
    View in: PubMed
    Score: 0.020
  68. Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Pharmacol Res. 1997 Jun; 35(6):517-22.
    View in: PubMed
    Score: 0.020
  69. Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. Hum Gene Ther. 1997 Feb 10; 8(3):341-7.
    View in: PubMed
    Score: 0.019
  70. Tissue kallikrein-binding protein reduces blood pressure in transgenic mice. J Biol Chem. 1996 Nov 01; 271(44):27590-4.
    View in: PubMed
    Score: 0.019
  71. High-salt diet upregulates kininogen and downregulates tissue kallikrein expression in Dahl-SS and SHR rats. Am J Physiol. 1996 Oct; 271(4 Pt 2):F824-30.
    View in: PubMed
    Score: 0.019
  72. Differential regulation of kallikrein, kininogen, and kallikrein-binding protein in arterial hypertensive rats. Am J Physiol. 1996 Jul; 271(1 Pt 2):F78-86.
    View in: PubMed
    Score: 0.019
  73. Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hum Gene Ther. 1996 May 20; 7(8):901-11.
    View in: PubMed
    Score: 0.018
  74. Functional analysis of human tissue kallikrein in transgenic mouse models. Hypertension. 1996 Mar; 27(3 Pt 2):491-4.
    View in: PubMed
    Score: 0.018
  75. Regulatory elements in the promoter region of the renal kallikrein gene in normotensive vs hypertensive rats. Biochem Biophys Res Commun. 1995 Dec 05; 217(1):113-22.
    View in: PubMed
    Score: 0.018
  76. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest. 1995 Apr; 95(4):1710-6.
    View in: PubMed
    Score: 0.017
  77. Cloning, sequence analysis and expression of the gene encoding the mouse bradykinin B2 receptor. Gene. 1994 Nov 18; 149(2):283-8.
    View in: PubMed
    Score: 0.017
  78. Subcellular distribution of tissue kallikrein and Na,K-ATPase alpha-subunit in rat parotid striated duct cells. Cell Tissue Res. 1994 Mar; 275(3):407-17.
    View in: PubMed
    Score: 0.016
  79. Expression and characterization of rat kallikrein-binding protein in Escherichia coli. Biochem J. 1993 Jun 15; 292 ( Pt 3):825-32.
    View in: PubMed
    Score: 0.015
  80. Regulation of kininogen gene expression and localization in the lung after monocrotaline-induced pulmonary hypertension in rats. Proc Soc Exp Biol Med. 1993 Jun; 203(2):243-50.
    View in: PubMed
    Score: 0.015
  81. Screening of complementary DNA library using radiolabeled antigen. Methods Enzymol. 1993; 217:325-35.
    View in: PubMed
    Score: 0.015
  82. Biochemical characterization and substrate specificity of rat prostate kallikrein (S3): comparison with tissue kallikrein, tonin and T-kininogenase. Biochim Biophys Acta. 1992 Jun 24; 1121(3):309-16.
    View in: PubMed
    Score: 0.014
  83. Differential regulation of kininogen gene expression by estrogen and progesterone in vivo. Biochim Biophys Acta. 1992 Jun 15; 1131(2):145-51.
    View in: PubMed
    Score: 0.014
  84. Tissue kallikrein activation of the epithelial Na channel. Am J Physiol Renal Physiol. 2012 Aug 15; 303(4):F540-50.
    View in: PubMed
    Score: 0.014
  85. In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein. J Lab Clin Med. 1992 May; 119(5):514-21.
    View in: PubMed
    Score: 0.014
  86. Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther. 2012 Aug; 23(8):859-70.
    View in: PubMed
    Score: 0.014
  87. Expression of kallikrein-binding protein and alpha 1-antitrypsin genes in response to sex hormones, growth, inflammation and hypertension. Agents Actions Suppl. 1992; 38 ( Pt 1):174-81.
    View in: PubMed
    Score: 0.014
  88. Kininogen and kinin in experimental spinal cord injury. J Neurochem. 1991 Sep; 57(3):975-80.
    View in: PubMed
    Score: 0.013
  89. Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem. 1990 Sep 25; 265(27):16394-401.
    View in: PubMed
    Score: 0.012
  90. Identification, purification, and localization of tissue kallikrein in rat heart. Biochem J. 1990 May 01; 267(3):639-46.
    View in: PubMed
    Score: 0.012
  91. Purification and characterization of a kallikrein-like T-kininogenase. J Biol Chem. 1990 Feb 15; 265(5):2822-7.
    View in: PubMed
    Score: 0.012
  92. Molecular cloning and primary structure of rat alpha 1-antitrypsin. Biochemistry. 1990 Jan 16; 29(2):323-9.
    View in: PubMed
    Score: 0.012
  93. Co-localization of a kallikrein-like serine protease (arginine esterase A) and atrial natriuretic peptide in rat atrium. J Histochem Cytochem. 1989 Dec; 37(12):1913-7.
    View in: PubMed
    Score: 0.012
  94. Sex dimorphism and inflammatory regulation of T-kininogen and T-kininogenase. Biochim Biophys Acta. 1989 Jun 27; 991(3):477-83.
    View in: PubMed
    Score: 0.011
  95. Renal kallikrein mRNA localization by in situ hybridization. Kidney Int. 1989 Jun; 35(6):1324-9.
    View in: PubMed
    Score: 0.011
  96. Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Hum Gene Ther. 2009 Feb; 20(2):147-58.
    View in: PubMed
    Score: 0.011
  97. Structural analysis of a rat renal kallikrein gene. Adv Exp Med Biol. 1989; 247A:73-80.
    View in: PubMed
    Score: 0.011
  98. Sex dimorphism and estrogen regulation of kininogens in rat serum, adrenal gland and kidney. Adv Exp Med Biol. 1989; 247B:297-303.
    View in: PubMed
    Score: 0.011
  99. Enhanced specificity in immunoscreening of expression cDNA clones using radiolabeled antigen overlay. Biotechniques. 1989 Jan; 7(1):68-72.
    View in: PubMed
    Score: 0.011
  100. Comparison of the distribution of tissue kallikrein and esterase A, a kallikrein-like enzyme, in rat kidney using specific monoclonal antibodies. J Histochem Cytochem. 1988 Oct; 36(10):1251-4.
    View in: PubMed
    Score: 0.011
  101. A major difference of kallikrein-binding protein in spontaneously hypertensive versus normotensive rats. J Hypertens. 1988 Jul; 6(7):551-7.
    View in: PubMed
    Score: 0.011
  102. Immunocytochemical localization of a kallikrein-like serine protease (esterase A) in rat salivary glands. Anat Rec. 1988 May; 221(1):475-81.
    View in: PubMed
    Score: 0.011
  103. Tissue distribution and kininogen gene expression after acute-phase inflammation. Biochim Biophys Acta. 1988 Mar 17; 964(3):329-39.
    View in: PubMed
    Score: 0.010
  104. Circulating autoantibodies to mammalian tissue kallikreins. Proc Soc Exp Biol Med. 1988 Mar; 187(3):320-6.
    View in: PubMed
    Score: 0.010
  105. Identification and expression of kallikrein gene family in rat submandibular and prostate glands using monoclonal antibodies as specific probes. Biochim Biophys Acta. 1987 Dec 08; 910(3):233-9.
    View in: PubMed
    Score: 0.010
  106. Rat urinary kallikrein localization in kidney: effects of fixation. Histochem J. 1987 Dec; 19(12):633-42.
    View in: PubMed
    Score: 0.010
  107. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides. 2007 Jul; 28(7):1383-9.
    View in: PubMed
    Score: 0.010
  108. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007 May; 148(5):2016-26.
    View in: PubMed
    Score: 0.010
  109. Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury. Free Radic Biol Med. 2006 Oct 15; 41(8):1304-14.
    View in: PubMed
    Score: 0.009
  110. Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp Neurol. 2006 Feb; 197(2):521-30.
    View in: PubMed
    Score: 0.009
  111. Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes. 2005 May; 54(5):1573-80.
    View in: PubMed
    Score: 0.009
  112. Adrenomedullin gene delivery protects against cerebral ischemic injury by promoting astrocyte migration and survival. Hum Gene Ther. 2004 Dec; 15(12):1243-54.
    View in: PubMed
    Score: 0.008
  113. Encapsulated transgene cells attenuate hypertension, cardiac hypertrophy and enhance renal function in Goldblatt hypertensive rats. J Gene Med. 2004 Jul; 6(7):786-97.
    View in: PubMed
    Score: 0.008
  114. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension. 2003 Nov; 42(5):1026-33.
    View in: PubMed
    Score: 0.008
  115. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol. 2003 Aug; 23(16):5726-37.
    View in: PubMed
    Score: 0.008
  116. Adrenomedullin gene delivery inhibits neointima formation in rat artery after balloon angioplasty. Regul Pept. 2003 Apr 15; 112(1-3):115-20.
    View in: PubMed
    Score: 0.007
  117. Adenovirus-mediated human prostasin gene delivery is linked to increased aldosterone production and hypertension in rats. Am J Physiol Regul Integr Comp Physiol. 2003 Apr; 284(4):R1031-6.
    View in: PubMed
    Score: 0.007
  118. Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension. J Biol Chem. 2002 Sep 20; 277(38):34708-16.
    View in: PubMed
    Score: 0.007
  119. Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol. 2001 Jun; 280(6):F964-71.
    View in: PubMed
    Score: 0.007
  120. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 2000 Dec; 36(6):995-1001.
    View in: PubMed
    Score: 0.006
  121. Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology. 1999 Oct 15; 44(1-2):57-65.
    View in: PubMed
    Score: 0.006
  122. Immunohistochemical localization of kininogen in rat spinal cord and brain. Exp Neurol. 1999 Oct; 159(2):528-37.
    View in: PubMed
    Score: 0.006
  123. Kallikrein-binding protein is induced by growth hormone in the dwarf rat. FASEB J. 1999 Oct; 13(13):1839-44.
    View in: PubMed
    Score: 0.006
  124. Atrial natriuretic peptide gene delivery attenuates gentamycin-induced nephrotoxicity in rats. Nephrol Dial Transplant. 1999 Jun; 14(6):1376-84.
    View in: PubMed
    Score: 0.006
  125. Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension. 1999 Jan; 33(1 Pt 2):219-24.
    View in: PubMed
    Score: 0.006
  126. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther. 1998 Jul 01; 9(10):1429-38.
    View in: PubMed
    Score: 0.005
  127. Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. Hypertens Res. 1997 Dec; 20(4):269-77.
    View in: PubMed
    Score: 0.005
  128. Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 1997 Mar; 38(3):658-64.
    View in: PubMed
    Score: 0.005
  129. Expression and localization of human kallistatin in rat submandibular gland after intracapsular gene injection. Biochem Biophys Res Commun. 1997 Feb 13; 231(2):494-8.
    View in: PubMed
    Score: 0.005
  130. Identification and characterization of two promoters of rat kallikrein-binding protein gene. Biochim Biophys Acta. 1996 Jul 17; 1307(3):285-93.
    View in: PubMed
    Score: 0.005
  131. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension. 1995 Dec; 26(6 Pt 1):847-53.
    View in: PubMed
    Score: 0.004
  132. Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension. 1995 Apr; 25(4 Pt 2):715-9.
    View in: PubMed
    Score: 0.004
  133. Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. J Biol Chem. 1995 Jan 06; 270(1):451-5.
    View in: PubMed
    Score: 0.004
  134. Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. Genomics. 1994 Sep 15; 23(2):362-9.
    View in: PubMed
    Score: 0.004
  135. Molecular cloning, sequence analysis, and chromosomal localization of the human protease inhibitor 4 (kallistatin) gene (PI4). Genomics. 1994 Sep 15; 23(2):370-8.
    View in: PubMed
    Score: 0.004
  136. Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. J Biol Chem. 1993 Nov 15; 268(32):24498-505.
    View in: PubMed
    Score: 0.004
  137. Molecular cloning and characterization of rKlk10, a cDNA encoding T-kininogenase from rat submandibular gland and kidney. Biochemistry. 1992 Nov 10; 31(44):10922-8.
    View in: PubMed
    Score: 0.004
  138. Specificity determinants of rat tissue kallikrein probed by site-directed mutagenesis. Protein Eng. 1992 Sep; 5(6):569-75.
    View in: PubMed
    Score: 0.004
  139. Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int. 1992 Apr; 41(4):789-95.
    View in: PubMed
    Score: 0.003
  140. Comparative studies on P2 specificity of wild-type rat tissue kallikrein, Y99H:W215G mutant and tonin. Agents Actions Suppl. 1992; 38 ( Pt 1):59-65.
    View in: PubMed
    Score: 0.003
  141. Localization of kallikrein gene family proteases in rat tissues. Agents Actions Suppl. 1992; 38 ( Pt 1):595-602.
    View in: PubMed
    Score: 0.003
  142. Molecular cloning and sequence analysis of the mouse kallikrein-binding protein gene. Biochim Biophys Acta. 1991 Dec 02; 1129(1):127-30.
    View in: PubMed
    Score: 0.003
  143. Molecular cloning and analysis of the rat kallikrein-binding protein gene. J Biol Chem. 1991 Aug 25; 266(24):16029-36.
    View in: PubMed
    Score: 0.003
  144. Purification and characterization of recombinant tissue kallikrein from Escherichia coli and yeast. Biochem J. 1991 May 15; 276 ( Pt 1):63-71.
    View in: PubMed
    Score: 0.003
  145. Kallikrein multigene families and the regulation of their expression. J Cardiovasc Pharmacol. 1990; 15 Suppl 6:S7-16.
    View in: PubMed
    Score: 0.003
  146. Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J Hypertens. 1989 Nov; 7(11):865-71.
    View in: PubMed
    Score: 0.003
  147. Characterization of genes encoding rat tonin and a kallikrein-like serine protease. Biochemistry. 1989 Jun 27; 28(13):5334-43.
    View in: PubMed
    Score: 0.003
  148. Arachidonic acid and its metabolites in cerebral ischemia. Ann N Y Acad Sci. 1989; 559:282-95.
    View in: PubMed
    Score: 0.003
  149. Molecular cloning and characterization of two rat renal kallikrein genes. Biochemistry. 1988 Sep 20; 27(19):7189-96.
    View in: PubMed
    Score: 0.003
  150. Identification of latent tissue kallikrein, prolactin and growth hormone secretion in GH3 pituitary cells using modified radioimmunoassays. Mol Cell Endocrinol. 1988 Jan; 55(1):21-31.
    View in: PubMed
    Score: 0.003
  151. Identification of tonin in brain and exocrine tissues and in the cell-free translation products encoded by the mRNA of these tissues. Biochem J. 1987 Dec 01; 248(2):477-81.
    View in: PubMed
    Score: 0.003
  152. Abnormal regulation of renal kallikrein in experimental diabetes. Effects of insulin on prokallikrein synthesis and activation. J Clin Invest. 1987 Dec; 80(6):1651-9.
    View in: PubMed
    Score: 0.003
  153. Identification and characterization of a tissue kallikrein in rat skeletal muscles. Biochem J. 1987 May 01; 243(3):773-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.